Thrombin Functions and Antithrombotic Intervention

• References

• 1 Fenton II JW, Fasco MJ, Stackrow AB, Aronson DL, Young AM, Finlay son JS. Human thrombins. Production, evaluation, and properties of cx-thrombin. J Biol Chem 1977; 252: 3587-3598
• 2 Fenton II JW, Landis BH, Walz DA, Finlayson JS. In: Chemistry and Biology of Thrombin. Lundblad RL, Fenton II JW, Mann KG. (eds) Ann Arbor Science Publishers; Ann Arbor: 1977. pp 43-70
• 3 Fenton II JW. Thrombin specificity. Ann NY Acad Sci 1981; 370: 468-495
• 4 Fenton II JW. Thrombin. Ann NY Acad Sci 1986; 485: 5-15
• 5 Fenton II JW. Thrombin bioregulatory functions. Adv Clin Enzymol 1988; 6: 186-193
• 6 Fenton II JW. Regulation of thrombin generation and functions. Semin Thromb Hemost 1988; 14: 234-240
• 7 Fenton II JW, Ofosu FA, Moon DG, Maraganore JM. Thrombin structure and function: why thrombin is the primary target for antithrombotics. Blood Coagul Fibrinolys 1991; 2: 69-75
• 8 Fenton II JW, Ofosu FA, Brezniak DV, Hassouna HI. Understanding thrombin and hemostasis. Hematol/Oncol Clin N Am 1993; 7: 1107-1119
• 9 Stubbs MT, Bode W. A player of many parts: the spotlight falls on thrombin’s structure. Thromb Res 1993; 69: 1-58
• 10 Irwin DM, Robertson KA, MacGillivray TA. Structure and evolution of the bovine prothrombin gene. J Mol Biol 1988; 200: 31-45
• 11 Iwanaga S, Miyata T, Tokunaga F, Muta T. Molecular mechanism of hemolymph clotting system in limulus. Thromb Res 1992; 68: 1-32
• 12 Vu T-KH, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64: 1057-1068
• 13 Rasmussen UB, Vouret-Craviari V, Jallot S, Schlesinger Y, Pages G, Parirani A, Lecocq J-P, Pouyssegur J, Van Obberghen-Schilling E. DNA cloning and expression of a hamster a-thrombin receptor coupled to Ca²⁺ mobilization. FEBS Lett 1991; 288: 123-128
• 14 Zhong C-H, Hayzer DA, Corson MA, Runge MS. Molecular cloning of the rat vascular smooth muscle thrombin receptor: evidence for in vitro regulation by basic fibroblast growth factor. J Biol Chem 1992; 267: 16975-16979
• 15 Natarjan S, Riexinger D, Peluso M, Seiler SM. “Tethered ligand” derived pentapeptide agonists of thrombin receptor: a study of side chain requirements for human platelet activation and GTPase stimulation. Int J Peptide Protein Res 1994; 6: 1-7
• 16 Ogletree ML, Natarajan S, Seiler SM. Thrombin receptors as drug discovery targets. Persp Drug Disc Design 1994; 1: 527-536
• 17 Soifer SJ, Peters KG, O’Keefe J, Coughlin ST. Disparate temporal expression of the prothrombin and thrombin receptor genes during mouse development. Am J Pathol 1994; 144: 60-69
• 18 Ofosu FA, Hirsh J, Esmon CT, Modi GJ, Smith LM, Anvari N, Buchanan MR, Fenton II JW, Blajchman MA. Unfractionated heparin inhibits thrombin-catalyzed amplification reactions of coagulation more efficiently than those catalyzed by factor Xa. Biochem J 1989; 257: 143-150
• 19 Yang SJ, Blajchman MA, Graven S, Smith LM, Anvari N, Ofosu FA. Activation of factor V during intrinsic and extrinsic coagulation. Inhibition by heparin, hirudin and D-Phe-Pro-Arg-CH_sCl. Biochem J 1990; 272: 399-406
• 20 Ofosu FA, Fenton II JW, Maraganore JM, Blajchman MA, Yang X, Smith L, Anvari N, Buchanan MR, Hirsh J. Inhibition of the amplification reaction of blood coagulation by site-specific inhibitors of cx-thrombin. Biochem J 1992; 283: 893-897
• 21 Bing DH, Laura R, Robison DJ, Furie B, Furie BC, Feldmann RJ. A computer-generated three-dimensional model of the B chain of bovine cx-thrombin. Ann NY Acad Sci 1981; 370: 496-510
• 22 Fenton II JW, Bing DH. Thrombin active-site regions. Semin Thromb Hemost 1986; 12: 200-220
• 23 Bode W, Mayr I, Baumann V, Huber R, Stone SR, Hofsteenge J. The refined 1.9 A crystal structure of human cx-thrombin: interaction with D-Phe-Pro- Arg chloromethyl ketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J 1989; 8: 3467-3475
• 24 Witting JI, Bourdon P, Brezniak DV, Maraganore JM, Fenton II JW. Thrombin specific inhibition by and slow cleavage of hirulog-1. BiochemI 1992; 283: 737-743
• 25 Witting JI, Bourdon P, Maraganore JM, Fenton II JW. Hirulog-1 and -B2 thrombin specificity. Biochem J 1992; 287: 663-664
• 26 Wilner GD, Danitz MP, Mudd SM, Hsieh KH, Fenton II JW. Selective immobilization of a-thrombin by surface-bound fibrin. J Lab Clin Med 1981; 97: 403-411
• 27 Lincoff AM, Popma JJ, Ellis SG, Hacker TA, Topol Ej. Abrupt vessel closure complicating coronary angioplasty, clinical angiographic therapeutic. J Am Coll Cardol 1992; 19: 926-933
• 28 Liu L, Dewar L, Song Y, Kulczcky M, Blajchman MA, Fenton II JW, Andrew M, Delorme M, Ginsberg J, Preissner KT, Ofosu FA. Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo. Thromb Haemost. 1995 in press
• 29 Weitz JJ, Hudoba M, Massel D, Maraganore J, Hirsch J. Clot- bound thrombin is protected from inactivation by heparin-antithrom- bin III but is susceptible to inactivation by antithrombin Ill-indepen- dent inhibitors. J Clin Invest 1990; 86: 385-391
• 30 Bittl JBittl. Hirulog during PTCA for post-infarction and unstable angina. George Washington University 10th International Workshop on Thrombolysis and Interventional Therapy in Acute Myocardial Infarction 13.11.1994. Dallas, TX:
• 31 Fenton II JW. Leeches to hirulogs and other thrombin-directed antithrombotics. Hematol/Oncol Clin North Am 1992; 6: 1121-1129
• 32 Fenton II JW, Olson TA, Zabinski MP, Wilner DG. Anion-binding exosite of human a-thrombin and fibrin(ogen) recognition. Biochemistry 1988; 27: 7106-7112
• 33 Malik AB, Fenton II JW. Thrombin-mediated increase in vascular endothelial permeability. Semin Thromb Hemost 1992; 18: 193-199
• 34 Brezniak DV, Brower MS, Witting JI, Walz DA, Fenton II JW. Human α to ζ-thrombin cleavage occurs with neutrophil cathepsin G or chymotrypsin while fibrinogen clotting activity is retained. Biochemistry 1990; 29: 3536-3542
• 35 Bar-Shavit R, Sabbah V, Lampugnani MG, Marchisio PC, Fenton II JW, Vlodavsky I, Dejane E. An Arg-Gly-Asp sequence within thrombin promotes endothelial cell adhesion. J Cell Biol 1991; 112: 335-344
• 36 Carney DH, Mann R, Redin WR, Pernia SD, Berry D, Heggers JP, Hayward PG, Robson MC, Christie J, Annabli C, Fenton II JW, Glenn KC. Enhancement of incisional wound healing and neovascularization in normal rats by thrombin and synthetic thrombin receptor-activating peptides. J Clin Invest 1992; 89: 1469-1477
• 37 Garcia JG N, Siflinger-Birnboim A, Bizios R, Del Vecchio PJ, Fenton II JW, Malik AB. Thrombin-induced increases in an albumin transport across cultured endothelial monolayers. J Cell Physiol 1986; 128: 96-104
• 38 Fenton II JW, Ofosu FA. Thrombin-mediated events implicated in post-thrombotic recovery. In Angiogenesis: Molecular Biology, Clinical Aspects. Maragoudakis ME. (ed) Plenum Press; New York: 1994. pp 253-263
• 39 McNamara CA, Sarembock IJ, Gimple LW, Fenton II JW, Coughlin SR, Owens GK. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. J Clin Invest 1993; 91: 91-98
• 40 Nellsen NA, Soifer SJ, O’Keefe J, Vu TK, Charo IF, Coughlin SR. Thrombin receptor expression in normal and atherosclerotic human arteries. J Clin Invest 1992; 90: 1614-1621
• 41 Wilcox JN, Rodriquez J, Subramanian R, Ollerenshaw J, Zhong C, Jayer DH, Horaist C, Hanson SR, Lumsden A, Salam TA, Kelly AB, Harker LA, Runge M. Characterization of thrombin receptor expression during vascular lesion formation. Circ Res 1994; 75: 1029-1038
• 42 Sarembock IJ, Gertz SD, Gimple LW, Owen RM, Powers ER, Roberts WC. Effectiveness of recombinant desulphatohirudin (CGP 39393) in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation 1991; 84: 232-243
• 43 Levin EG, Stern DM, Nawroth PP, Marlar RA, Fair DS, Fenton II JW, Harker LA. Specificity of the thrombin-induced release of tissue plasminogen activator from cultured human endothelial cells. Thromb Haemost 1986; 56: 115-119
• 44 Catalfamo JL, Ander TT, Fenton II JW. Thrombin receptoractivating peptides unlike thrombin are insufficient for platelet activation in most species. Thromb Haemost 1993; 69: 1195 (abstr)
• 45 Connolly TM, Condra C, Feng D-M, Cook JJ, Stranieri M, Reilly CF, Nutt RF, Gould RH. Species variability in platelet and other cellular responsiveness to thrombin receptor-derived peptides. Thromb Haemost 1994; 72: 627-633
• 46 Ferraris VA, Rodriquez E, Ferraris SP, Huang M, Gupta A, Bennett JA, Andersen TT, Dunn H, Fenton II JW, Smith JB. Platelet aggregation abnormalities after cardiopulmonary bypass. Blood 1994; 83: 299-300
• 47 Rydel TJ, Ravishandraw KG, Tulinsky A, Bode W, Huber R, Roitsch C, Fenton II JW. The structure of a complex of recombinant hirudin and human a-thrombin. Science 1990; 249: 277-280
• 48 Fenton II JW, Ni F, Witting JI, Brezniak DV, Andersen TT, Malik AB. The rational design of thrombin-directed antithrombotics. Adv Exptl Biol Med 1992; 340: 1-14
• 49 De Cristofaro R, Fenton II JW, Di Cera E. Modulation of thrombin- hirudin interaction by specific ion effects. J Mol Biol 1992; 226: 263-269
• 50 Konno S, Fenton II JW, Villanueva GB. Analysis of the secondary structure of hirudin and the conformational change upon interaction with thrombin. Arch Biochem Biophys 1988; 267: 158-166
• 51 Naski MC, Fenton II JW, Maraganore JM, Oson ST, Shafer JA. The C-terminal domain of hirudin on fibrinogen: and exosite directed competitive inhibitor of the action of a-thrombin on fibrinogen. J Biol Chem 1990; 265: 13484-13489
• 52 Kane WH, Davie EW. Blood coagulation factors V and VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. Blood 1988; 71: 539-555
• 53 Church FC, Pratt CW, Noyes CM, Kalayanamit T, Sherrill GB, Tobin RB, Meade JB. Structural and functional properties of human a-thrombin, phosphopyridoxylated a-thrombin, and Y_t-thrombin. Identification of lysyl residues in a-thrombin that are critical for heparin and fibrin(ogen) interactions. J Biol Chem 1989; 264: 18419-18425
• 54 Fenton II JW, Campbell WP, Harrington JC, Miller KD. Large scale preparation and preliminary characterization of human thrombin. Biochim Biophys Acta 1971; 229: 26-32
• 55 Sonder SA, Fenton II JW. Proflavin binding within the fibrinopep- tide groove adjacent to the catalytic site of human a-thrombin. Biochemistry 1984; 23: 1818-1823
• 56 Gaffney PJ, Heath AB, Fenton II JW. A collaborative study to establish an international standard for alpha-thrombin. Thromb Haemost 1992; 67: 424-427
• 57 Chen LB, Buchanan JM. Mitogenic activity of blood components. I. Thrombin and prothrombin. Proc Natl Acad Sci USA 1975; 72: 131-135
• 58 Markwardt F. Hirudin and derivatives as anticoagulant agents. Thromb Haemost 1991; 66: 141-152
• 59 Fenton II JW, Ni F, Witting JI, Brezniak DV, Anderson TT, Malik AB. The rational design of thrombin-directed antithrombotics. Adv Expt Med Biol 1993; 340: 1-13
• 60 Maraganore JMaraganore. Thrombin, thrombin inhibitors, and the arterial thrombotic process. Thromb Haemost 1993; 70: 208-211
• 61 Dickels DDickels. Gene transfer in the treatment of thrombosis. Thromb Haemost 1993; 70: 198-201
• 62 Nabel EG, Nabel GJ. Direct gene transfer: basic studies and human therapies. Thromb Haemost 1993; 70: 202-203
• 63 Wittig JI, Brezniak DV, Hayes JR, Fenton II JW. Human α and ζ thrombin inhibition by recombinant HV1 and HV2K47 hirudins. Thromb Res 1991; 63: 473-479